↓ Skip to main content

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

Overview of attention for article published in Journal of Translational Medicine, December 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma
Published in
Journal of Translational Medicine, December 2015
DOI 10.1186/s12967-015-0743-2
Pubmed ID
Authors

Feng Xue, Brandon W. Higgs, Jiaqi Huang, Chris Morehouse, Wei Zhu, Xin Yao, Philip Brohawn, Zhan Xiao, Yinong Sebastian, Zheng Liu, Yun Xia, Dong Shen, Mike Kuziora, Zhengwei Dong, Hulin Han, Yi Gu, Jianren Gu, Qiang Xia, Yihong Yao

Abstract

Orthotopic liver transplantation (OLT) can be an effective treatment option for certain patients with early stage hepatocellular carcinoma (HCC) meeting Milan, UCSF, or Hangzhou criteria. However, HCC recurrence rates post-OLT range from 20 to 40 %, with limited follow-up options. Elucidating genetic drivers common to primary and post-OLT recurrent tumors may further our understanding and help identify predictive biomarkers of recurrence-both to ultimately help manage clinical decisions for patients undergoing OLT. Whole exome and RNA sequencing in matched primary and recurrent tumors, normal adjacent tissues, and blood from four Chinese HCC patients was conducted. SiRNA knockdown and both qRT-PCR and Western assays were performed on PLCPRF5, SNU449 and HEPG2 cell lines; immunohistochemistry and RNA Sequencing were conducted on the primary tumors of Chinese HCC patients who experienced tumor recurrence post-OLT (n = 9) or did not experience tumor recurrence (n = 12). In three independent HCC studies of patients undergoing transplantation (n = 21) or surgical resection (n = 242, n = 44) of primary tumors (total n = 307), HERC5 mRNA under-expression correlated with shorter: time to tumor recurrence (p = 0.007 and 0.02) and overall survival (p = 0.0063 and 0.023), even after adjustment for relevant clinical variables. HERC5 loss drives CCL20 mRNA and protein over-expression and associates with regulatory T cell infiltration as measured by FOXP3 expression. Further, matched primary and recurrent tumors from the 4 HCC patients indicated clonal selection advantage of Wnt signaling activation and CDKN2A inactivation. HERC5 plays a crucial role in HCC immune evasion and has clinical relevance as a reproducible prognostic marker for risk of tumor recurrence and survival in patients.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 18%
Student > Bachelor 3 18%
Student > Doctoral Student 2 12%
Student > Master 2 12%
Other 1 6%
Other 1 6%
Unknown 5 29%
Readers by discipline Count As %
Agricultural and Biological Sciences 4 24%
Biochemistry, Genetics and Molecular Biology 3 18%
Nursing and Health Professions 1 6%
Psychology 1 6%
Medicine and Dentistry 1 6%
Other 1 6%
Unknown 6 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2016.
All research outputs
#3,568,802
of 7,909,849 outputs
Outputs from Journal of Translational Medicine
#654
of 1,787 outputs
Outputs of similar age
#120,438
of 299,820 outputs
Outputs of similar age from Journal of Translational Medicine
#27
of 83 outputs
Altmetric has tracked 7,909,849 research outputs across all sources so far. This one has received more attention than most of these and is in the 53rd percentile.
So far Altmetric has tracked 1,787 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.